TSZY(SZ:002872)2023-04-26 16:00Financial Performance - Tiansheng Pharmaceutical reported a revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[1]. - The company has set a revenue target of RMB 1.5 billion for 2023, which reflects a growth forecast of 25%[1]. - The company's operating revenue for 2022 was ¥606,992,213.55, a decrease of 17.61% compared to ¥736,685,771.58 in 2021[22]. - The total revenue for 2022 was ¥606,992,213.55, a decrease of 17.61% compared to the previous year[55]. - The net profit attributable to shareholders was -¥90,563,424.65 in 2022, representing a decline of 33.56% from -¥67,805,395.08 in 2021[22]. - The company reported a net profit attributable to shareholders in Q4 2022 was -¥27,981,426.64, showing a significant loss compared to previous quarters[27]. - The company achieved a net profit of RMB 300 million, which is a 15% increase compared to the previous year[197]. - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to RMB 1.8 billion[198]. Research and Development - The company plans to invest RMB 200 million in R&D for new drug development in 2023, focusing on oncology and chronic diseases[1]. - Research and development expenses amounted to ¥34,269,400, an increase of 17.19% year-on-year[58]. - The company is focusing on expanding its product line and enhancing process quality through various new applications and approvals[74]. - The company plans to increase R&D investment in traditional Chinese medicine and chemical drugs, focusing on high-end and basic products, with a commitment to developing innovative drugs and health products[107]. - Research and development expenses increased by 10%, totaling RMB 150 million, focusing on innovative drug formulations[198]. Market Expansion - Tiansheng Pharmaceutical is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2023[1]. - The company plans to enhance its digital marketing efforts, aiming for a 50% increase in online sales channels[149]. - The company is expanding its market presence, targeting a 20% market share within the next three years[196]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[1]. Product Development - Tiansheng has successfully launched two new products in Q4 2022, contributing an additional RMB 100 million in revenue[1]. - New product launches are expected to contribute an additional RMB 200 million in revenue in the upcoming fiscal year[197]. - The company has approved multiple new products, including Lidocaine Hydrochloride Injection and Torasemide Injection, which are expected to positively impact performance[74]. Financial Management - The company has not declared any cash dividends for 2022, opting to reinvest profits into business expansion[1]. - The company has a robust marketing network, covering over 15,000 medical institutions, reflecting its strong market position and brand advantage[54]. - The company has established a comprehensive quality management system, ensuring that all materials undergo strict quality inspections, with non-compliant materials not allowed in production[46]. - The company has a structured training system in place, focusing on internal career development and professional skill enhancement for employees[165]. Risks and Challenges - The company faces potential risks including regulatory changes and market competition, which could impact future performance[1]. - The pharmaceutical industry faces significant policy risks, including stricter regulations and quality standards, which could impact future development[114]. - Price reductions in pharmaceuticals due to government policies and market competition pose risks to the company's profitability[118]. - The company is involved in a significant legal case regarding bribery, with a potential financial penalty of RMB 3.8 million[119]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of investor interests[126]. - The board of directors consists of 7 members, including 3 independent directors, and operates under strict governance rules[130]. - The company has implemented a transparent performance evaluation and incentive mechanism for its management team[132]. - The company maintains independence from its controlling shareholder in terms of business operations, personnel, assets, and financial management[136][138]. Environmental Responsibility - The company adheres to environmental protection laws and industry standards during the production of small-volume injectables and traditional Chinese medicine extracts[180]. - The company has established a wastewater treatment station that operates normally, with wastewater primarily sourced from equipment and floor cleaning, ensuring compliance with discharge standards[184]. - The company has implemented strict environmental protection measures in all construction projects, ensuring compliance with environmental impact assessments[181]. - The total environmental protection investment for 2022 was CNY 554,055.65, including CNY 512,300 for operation and maintenance of environmental facilities, CNY 8,000 for hazardous waste disposal, and CNY 32,500 for testing fees[185].